Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma
Laszlo Kari(The Wistar Institute), Louise C. Showe(The Wistar Institute), Wen-Hwai Horng(The Wistar Institute), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Johnston(The Wistar Institute), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dezső P. Virók(The Wistar Institute), Alain H. Rook(University of Pennsylvania), Michael K. Showe(The Wistar Institute), Celia Chang(The Wistar Institute), Maria Wysocka(University of Pennsylvania), Calen Nichols(The Wistar Institute), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust)
Cited by 208
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy
|New England Journal of Medicine|1987|1.2k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657